Association of HLA polymorphisms with post-transplant lymphoproliferative disorder in solid-organ transplant recipients

American Journal of Transplantation

Volumn 11, Issue 4, 2011, Pages 817-825

  Reshef, R ^a   Luskin, M R ^a   Kamoun, M ^b   Vardhanabhuti, S ^b   Tomaszewski, J E ^b   Stadtmauer, E A ^a   Porter, D L ^a   Heitjan, D F ^b   Tsai, De E ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

HLA; PTLD; solid organ transplantation

Indexed keywords

HLA A ANTIGEN; HLA A25 ANTIGEN; HLA A26 ANTIGEN; HLA ANTIGEN; HLA B ANTIGEN; HLA B38 ANTIGEN; HLA B65 ANTIGEN; HLA B8 ANTIGEN; HLA BW6 ANTIGEN; HLA DR ANTIGEN; HLA DR12 ANTIGEN; HLA DR3 ANTIGEN; HLA DR5 ANTIGEN; HLA DR6 ANTIGEN; HLA DR9 ANTIGEN; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; CAUCASIAN; CONTROLLED STUDY; DNA POLYMORPHISM; EPSTEIN BARR VIRUS; FEMALE; GENETIC ASSOCIATION; GENETIC RISK; GRAFT RECIPIENT; HAPLOTYPE; HETEROZYGOTE; HUMAN; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; ORGAN DONOR; ORGAN TRANSPLANTATION; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE; PRIORITY JOURNAL; RISK ASSESSMENT; SURVIVAL;

ADOLESCENT; ADULT; AGED; CASE-CONTROL STUDIES; COHORT STUDIES; FEMALE; GRAFT SURVIVAL; HLA ANTIGENS; HUMANS; LYMPHOPROLIFERATIVE DISORDERS; MALE; MIDDLE AGED; ORGAN TRANSPLANTATION; POLYMORPHISM, GENETIC; POSTOPERATIVE COMPLICATIONS; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79953236786     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2011.03454.x     Document Type: Article

References (55)

1. Murray JE, Wilson RE, Tilney Nl, et al,. Five years' experience in renal transplantation with immunosuppressive drugs: Survival, function, complications, and the role of lymphocyte depletion by thoracic duct fistula. Ann Surg 1968; 168: 416-435.
2. Penn I, Hammond W, Brettschneider L, Starzl TE,. Malignant lymphomas in transplantation patients. Transplant Proc 1969; 1: 106-112.
3. Opelz G, Dohler B,. Lymphomas after solid organ transplantation: A collaborative transplant study report. Am J Transplant 2004; 4: 222-230. (Pubitemid 38248525)
4. Opelz G, Henderson R,. Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients. Lancet 1993; 342: 1514-1516. (Pubitemid 23362168)
5. Nalesnik MA,. Posttransplantation lymphoproliferative disorders (PTLD): Current perspectives. Semin Thorac Cardiovasc Surg 1996; 8: 139-148.
6. Swerdlow SH, International Agency for Research on Cancer, World Health Organization. WHO classification of tumours of haematopoietic and lymphoid tissues, 4th Ed. Lyon, France: International Agency for Research on Cancer, 2008.
7. Epstein MA, Achong BG, Barr YM,. Virus particles in cultured lymphoblasts from burkitt's lymphoma. Lancet 1964; 1: 702-703.
8. Williams H, Crawford DH,. Epstein-Barr virus: The impact of scientific advances on clinical practice. Blood 2006; 107: 862-869. (Pubitemid 43156280)
9. Klein J, Sato A,. The HLA system-first of two parts. N Engl J Med 2000; 343: 702-709.
10. Subklewe M, Marquis R, Choquet S, et al,. Association of human leukocyte antigen haplotypes with posttransplant lymphoproliferative disease after solid organ transplantation. Transplantation 2006; 82: 1093-1100. (Pubitemid 44632126)
11. Pourfarziani V, Einollahi B, Taheri S, Nemati E, Nafar M, Kalantar E,. Associations of human leukocyte antigen (HLA) haplotypes with risk of developing lymphoproliferative disorders after renal transplantation. Ann Transplant 2007; 12: 16-22.
12. Bakker NA, van Imhoff GW, Verschuuren EA, van Son WJ, Van Der Heide JJ, Lems SP,. HLA antigens and post renal transplant lymphoproliferative disease: HLA-B matching is critical. Transplantation 2005; 80: 595-599. (Pubitemid 41377744)
13. Hjalgrim H, Rostgaard K, Johnson PC, et al,. HLA-A alleles and infectious mononucleosis suggest a critical role for cytotoxic T-cell response to EBV-related Hodgkin lymphoma. Proc Natl Acad Sci USA 2010; 107: 6400-6405.
14. Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M,. Report of the committee on Hodgkin's disease staging classification. Cancer Res 1971; 31: 1860-1861.
15. Eisenhauer EA, Therasse P, Bogaerts J, et al,. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-247.
16. Thorley-Lawson DA, Gross A,. Persistence of the Epstein-Barr virus and the origins of associated lymphomas. N Engl J Med 2004; 350: 1328-1337. (Pubitemid 38375368)
17. Richinson AB, Moss DJ,. Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection. Annu Rev Immunol 1997; 15: 405-431. (Pubitemid 27169287)
18. Subklewe M, Chahroudi A, Bickham K, et al,. Presentation of Epstein-Barr virus latency antigens to CD8 (+), interferon-gamma-secreting, T lymphocytes. Eur J Immunol 1999; 29: 3995-4001.
19. Madeleine MM, Johnson LG, Smith AG, et al,. Comprehensive analysis of HLA-A, HLA-B, HLA-C, HLA-DRB1, and HLA-DQB1 loci and squamous cell cervical cancer risk. Cancer Res 2008; 68: 3532-3539.
20. Madeleine MM, Brumback B, Cushing-Haugen KL, et al,. Human leukocyte antigen class II and cervical cancer risk: A population-based study. J Infect Dis 2002; 186: 1565-1574. (Pubitemid 35379632)
21. Wu Y, Liu B, Lin W, et al,. Human leukocyte antigen class II alleles and risk of cervical cancer in China. Hum Immunol 2007; 68: 192-200. (Pubitemid 46356649)
22. Sanjeevi CB, Hjelmström P, Hallmans G, et al,. Different HLA-DR-DQ haplotypes are associated with cervical intraepithelial neoplasia among human papillomavirus type-16 seropositive and seronegative Swedish women. Int J Cancer 1996; 68: 409-414. (Pubitemid 26414491)
23. Wang SS, Wheeler CM, Hildesheim A, et al,. Human leukocyte antigen class I and II alleles and risk of cervical neoplasia: Results from a population-based study in Costa Rica. J Infect Dis 2001; 184: 1310-1314. (Pubitemid 33055576)
24. Mann DL, Murray C, O'Donnell M, Blattner WA, Goedert JJ,. HLA antigen frequencies in HIV-1-related Kaposi's sarcoma. J Acquir Immune Defic Syndr. 1990; 3 (Suppl 1): S51-S55. (Pubitemid 20317571)
25. Dorak MT, Yee LJ, Tang J, et al,. HLA-B, -DRB1/3/4/5, and -DQB1 gene polymorphisms in human immunodeficiency virus-related Kaposi's sarcoma. J Med Virol 2005; 76: 302-310. (Pubitemid 40770884)
26. Gayà A, Esteve A, Casabona J, et al,. Amino acid residue at position 13 in HLA-DR beta chain plays a critical role in the development of Kaposi's sarcoma in AIDS patients. AIDS 2004; 18: 199-204. (Pubitemid 38253441)
27. Hildesheim A, Apple RJ, Chen CJ, et al,. Association of HLA class I and II alleles and extended haplotypes with nasopharyngeal carcinoma in Taiwan. J Natl Cancer Inst 2002; 94: 1780-1789. (Pubitemid 36004354)
28. Li X, Ghandri N, Piancatelli D, et al,. Associations between HLA class I alleles and the prevalence of nasopharyngeal carcinoma (NPC) among Tunisians. J Transl Med 2007; 5: 22.
29. Dardari R, Khyatti M, Jouhadi H, Benider A, Ettayebi H, Kahlain A,. Study of human leukocyte antigen class I phenotypes in Moroccan patients with nasopharyngeal carcinoma. Int J Cancer 2001; 92: 294-297. (Pubitemid 32225383)
30. David AL, Taylor GM, Gokhale D, Aplin JD, Seif MW, Tindall VR,. HLA-DQB1*03 and cervical intraepithelial neoplasia type III. Lancet 1992; 340: 52.
31. Vandenvelde C, De Foor M, van Beers D,. HLA-DOB1*03 and cervical intraepithelial neoplasia grades I-III. Lancet 1993; 341: 442-443. (Pubitemid 23048189)
32. Ioannidis JP, Skolnik PR, Chalmers TC, Lau J,. Human leukocyte antigen associations of epidemic Kaposi's sarcoma. AIDS 1995; 9: 649-651.
33. Maiers M, Gragert L, Klitz W,. High resolution HLA alleles and haplotypes in the US population. Hum Immunol 2007; 68: 779-788. (Pubitemid 47379974)
34. Kamper PM, Kjeldsen E, Clausen N, Bendix K, Hamilton-Dutoit S, d'Amore F,. Epstein-Barr virus-associated familial Hodgkin lymphoma: Paediatric onset in three of five siblings. Br J Haematol 2005; 129: 615-617. (Pubitemid 40825822)
35. Meguro A, Inoko H, Ota M, et al,. Genetics of Behçet disease inside and outside the MHC. Ann Rheum Dis 2010; 69: 747-754.
36. Brennan RM, Burrows SR,. A mechanism for the HLA-A*01-associated risk for EBV +Hodgkin lymphoma and infectious mononucleosis. Blood 2008; 112: 2589-2590.
37. Gulley ML, Swinnen LJ, Plaisance KT Jr,., Schnell C, Grogan TM, Schneider BG,. Tumor origin and CD 20 expression in posttransplant lymphoproliferative disorder occurring in solid organ transplant recipients: Implications for immune-based therapy. Transplantation 2003; 76: 959-964. (Pubitemid 37186027)
38. Chadburn A, Suciu-Foca N, Cesarman E, Reed E, Michler RE, Knowles DM,. Post-transplantation lymphoproliferative disorders arising in solid organ transplant recipients are usually of recipient origin. Am J Pathol 1995; 147: 1862-1870.
39. Cherqui D, Duvoux C, Plassa F, et al,. Lymphoproliferative disorder of donor origin in a liver transplant recipient: Complete remission after drastic reduction of immunosuppression without graft loss. Transplantation 1993; 56: 1023-1026. (Pubitemid 23321552)
40. Spiro IJ, Yandell DW, Li C, et al,. Brief report: Lymphoma of donor origin occurring in the porta hepatic of a transplanted liver. N Engl J Med 1993; 329: 27-29. (Pubitemid 23182875)
41. Armes JE, Angus P, Southey MC, et al,. Lymphoproliferative disease of donor origin arising in patients after orthotopic liver transplantation. Cancer 1994; 74: 2436-2441. (Pubitemid 24320845)
42. Horst D, van Leeuwen D, Croft NP, et al,. Specific targeting of the EBV lytic phase protein BNLF2a to the transporter associated with antigen processing results in impairment of HLA class I-restricted antigen presentation. J Immunol 2009; 182: 2313-2324.
43. Zeidler R, Eissner G, Meissner P, et al,. Downregulation of TAP1 in B lymphocytes by cellular and Epstein-Barr virus-encoded interleukin-10. Blood 1997; 90: 2390-2397. (Pubitemid 27392723)
44. Demanet C, Mulder A, Deneys V, et al,. Down-regulation of HLA-A and HLA-Bw6, but not HLA-Bw4, allospecificities in leukemic cells: An escape mechanism from CTL and NK attack? Blood 2004; 103: 3122-3130. (Pubitemid 38451690)
45. Middleton D, Diler AS, Meenagh A, Sleator C, Gourraud PA,. Killer immunoglobulin-like receptors (KIR2DL2 and/or KIR2DS2) in presence of their ligand (HLA-C1 group) protect against chronic myeloid leukaemia. Tissue Antigens 2009; 73: 553-560.
46. Flores-Villanueva PO, Yunis EJ, Delgado JC, et al,. Control of HIV-1 viremia and protection from AIDS are associated with HLA-Bw4 homozygosity. Proc Natl Acad Sci USA 2001; 98: 5140-5145. (Pubitemid 32397096)
47. Hislop AD, Palendira U, Leese AM, et al,. Impaired Epstein-Barr virus-specific CD8+ T cell function in X-linked lymphoproliferative disease is restricted to SLAM family positive B cell targets. Blood 2010; 116: 3249-3257.
48. Blaes AH, Cao Q, Wagner JE, Young JA, Weisdorf DJ, Brunstein CG,. Monitoring and preemptive rituximab therapy for Epstein-Barr virus reactivation after antithymocyte globulin containing nonmyeloablative conditioning for umbilical cord blood transplantation. Biol Blood Marrow Transplant 2010; 16: 287-291.
49. Ahmad I, Cau NV, Kwan J, et al,. Preemptive management of Epstein-Barr virus reactivation after hematopoietic stem-cell transplantation. Transplantation 2009; 87: 1240-1245.
50. Cox KL, Lawrence-Miyasaki LS, Garcia-Kennedy R, et al,. An increased incidence of Epstein-Barr virus infection and lymphoproliferative disorder in young children on FK506 after liver transplantation. Transplantation 1995; 59: 524-529.
51. Sokal EM, Antunes H, Beguin C, et al,. Early signs and risk factors for the increased incidence of Epstein-Barr virus-related post-transplant lymphoproliferative diseases in pediatric liver transplant recipients treated with tacrolimus. Transplantation 1997; 64: 1438-1442. (Pubitemid 27513623)
52. Dharnidharka VR, Sullivan EK, Stablein DM, Tejani AH, Harmon WE,. Risk factors for post-transplant lymphoproliferative disorder (PTLD) in pediatric kidney transplantation: A report of the North American pediatric renal transplant cooperative study (NAPRTCS). Transplantation 2001; 71: 1065-1068. (Pubitemid 32448820)
53. Webster AC, Woodroffe RC, Taylor RS, Chapman JR, Craig JC,. Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: Meta-analysis and meta-regression of randomised trial data. BMJ 2005; 331: 810-814. (Pubitemid 41442360)
54. Swinnen LJ, Costanzo-Nordin MR, Fisher SG, et al,. Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients. N Engl J Med 1990; 323: 1723-1728.
55. Durrbach A, Pestana JM, Pearson T, et al,. A phase III study of belatacept vs cyclosporine in kidney transplants from extended criteria donors (benefit-ext study). Am J Transplant 2010; 10: 571-581.